title: Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
abstract: OBJECTIVE
  The management of elderly patients with multiple myeloma is a relevant problem because it concerns a great number of patients. Patients with multiple myeloma who are very old or who have severe associated diseases have a dismal outcome. For these patients we retrospectively evaluated the effect of a mild approach with continuous low-dose melphalan and prednisone (cMP).
  
  
  METHODS
  109 patients with multiple myeloma, observed between 1985 and 2000, were treated with cMP; 67 were treated at time of diagnosis (group A; median age 78 years) and 42 as a second or subsequent line of therapy (group B; median age 72 years). The toxicity of the treatment was compared with a control group of 29 patients aged over 70 years, treated in the same institution with the conventional cyclical melphalan/prednisone regimen.
  
  
  RESULTS
  Major or minor responses were obtained in 32% of patients in group A and 13% of patients in group B. Disease was stabilised in 45% of group A and 47% of group B and progressed in 5 and 18%, respectively. Median survival was, respectively, 19 and 24 months in group A and B. Among the 42 patients who received cMP as a second-line therapy (group B), 36 (86%) had previously been treated according to the standard cyclical melphalan/prednisone schedule; of these 12 (33%) obtained a better M protein reduction after cMP compared with the previous response to first-line cyclical melphalan/prednisone. The cMP schedule was generally well tolerated, and the rate of haematological toxicity was lower than for a historical control group receiving cyclical melphalan/prednisone.
  
  
  CONCLUSIONS
  The cMP treatment schedule is well tolerated and results in a high proportion of patients with stable disease, with acceptable survival even in patients with advanced disease.
authors.affiliation: Department of Cellular Biotechnology and Hematology, La Sapienza University, Rome, Italy. pulsoni@bce.uniroma1.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Pulsoni
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Villivà
authors.forename: Elena
authors.initials: E
authors.lastname: Cavalieri
authors.forename: Paolo
authors.initials: P
authors.lastname: Falcucci
authors.forename: Giacinto
authors.initials: G
authors.lastname: La Verde
authors.forename: Roberta
authors.initials: R
authors.lastname: Matera
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Petrucci
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Tosti
authors.forename: Franco
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D008558:Melphalan; D011241:Prednisone